IBM's Watson Is Beginning To Pay Off
Following the aggressive hiring and estimated data acquisitions worth $5 billion, International Business Machines Corp. (NYSE: IBM) appears all set to benefit from the revenue monetization of Watson.
Morgan Stanley’s Katy L. Huberty maintained an Overweight rating on the company, while raising the price target from $140 to $168.
“Based on our Watson Customer Tracker, the business is on track to double announced customer in 2016 after a significant ramp last year,” Huberty mentioned, while adding that the revenue models included “revenue sharing, IP sharing, and IBM built solutions charged as-a-service.”
Although the revenue base might appear small at present, the analyst expects the SaaS-like model to lead to sustainable revenue streams in the long term.
Huberty also pointed out that there were significant market opportunities for Watson, with 320 million annual radiology images at $10 per image translating to a market that was over $3 billion in the U.S. alone.
In addition, Huberty also noted that there could be “even larger revenue opportunities to IBM if it can reduce the number of tests/images which often cost multiple thousands of dollars. Other revenue streams exist in helping match Oncology patients with drug trials.”
The company has already announced having entered into several hospital partnerships in the United States, and believes that there could be significant opportunity in the emerging markets, where there is a shortage of domain experts, while the growing patient population leads to high demand.
Latest Ratings for IBM
|Apr 2017||Berenberg||Initiates Coverage On||Sell|
|Jan 2017||Guggenheim||Initiates Coverage On||Neutral|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.